vs
Open Lending Corp（LPRO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Open Lending Corp的1.6倍（$30.3M vs $19.3M），Open Lending Corp同比增速更快（134.0% vs 43.0%），Open Lending Corp自由现金流更多（$-3.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -20.7%）
开放图书馆是互联网档案馆旗下的非盈利在线项目，旨在实现「每一本出版过的书都拥有专属网页」的目标，由亚伦·斯沃茨等多位开发者共同创立，项目获得了加州州立图书馆和卡勒-奥斯汀基金会的部分资助，为用户提供多种格式的公开领域书籍数字化副本在线阅览服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LPRO vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$19.3M
营收增速更快
LPRO
高出91.0%
43.0%
自由现金流更多
LPRO
多$49.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-20.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.3M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | 76.0% | — |
| 营业利润率 | 3.9% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 134.0% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-0.00 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPRORGNX
| Q4 25 | $19.3M | $30.3M | ||
| Q3 25 | $24.2M | $29.7M | ||
| Q2 25 | $25.3M | $21.4M | ||
| Q1 25 | $24.4M | $89.0M | ||
| Q4 24 | $-56.9M | $21.2M | ||
| Q3 24 | $23.5M | $24.2M | ||
| Q2 24 | $26.7M | $22.3M | ||
| Q1 24 | $30.7M | $15.6M |
净利润LPRORGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-7.6M | $-61.9M | ||
| Q2 25 | $1.0M | $-70.9M | ||
| Q1 25 | $617.0K | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $1.4M | $-59.6M | ||
| Q2 24 | $2.9M | $-53.0M | ||
| Q1 24 | $5.1M | $-63.3M |
毛利率LPRORGNX
| Q4 25 | 76.0% | — | ||
| Q3 25 | 78.0% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 75.1% | — | ||
| Q4 24 | 111.0% | 70.2% | ||
| Q3 24 | 73.9% | 48.8% | ||
| Q2 24 | 78.6% | 52.5% | ||
| Q1 24 | 81.3% | 72.6% |
营业利润率LPRORGNX
| Q4 25 | 3.9% | -190.0% | ||
| Q3 25 | -31.9% | -176.3% | ||
| Q2 25 | 4.6% | -296.3% | ||
| Q1 25 | 3.1% | 13.6% | ||
| Q4 24 | 138.0% | -242.1% | ||
| Q3 24 | 7.9% | -256.6% | ||
| Q2 24 | 14.9% | -251.3% | ||
| Q1 24 | 23.8% | -408.8% |
净利率LPRORGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -31.3% | -208.3% | ||
| Q2 25 | 4.1% | -331.8% | ||
| Q1 25 | 2.5% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 6.1% | -246.3% | ||
| Q2 24 | 10.9% | -237.7% | ||
| Q1 24 | 16.5% | -405.4% |
每股收益（稀释后）LPRORGNX
| Q4 25 | $-0.00 | $-1.30 | ||
| Q3 25 | $-0.06 | $-1.20 | ||
| Q2 25 | $0.01 | $-1.38 | ||
| Q1 25 | $0.01 | $0.12 | ||
| Q4 24 | $-1.20 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $0.04 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $176.6M | $230.1M |
| 总债务越低越好 | $84.8M | — |
| 股东权益账面价值 | $75.0M | $102.7M |
| 总资产 | $236.7M | $453.0M |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资LPRORGNX
| Q4 25 | $176.6M | $230.1M | ||
| Q3 25 | $222.1M | $274.2M | ||
| Q2 25 | $230.7M | $323.3M | ||
| Q1 25 | $236.2M | $267.9M | ||
| Q4 24 | $243.2M | $234.7M | ||
| Q3 24 | $250.2M | $255.5M | ||
| Q2 24 | $248.0M | $290.4M | ||
| Q1 24 | $247.0M | $338.7M |
总债务LPRORGNX
| Q4 25 | $84.8M | — | ||
| Q3 25 | $134.4M | — | ||
| Q2 25 | $136.1M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $139.7M | — | ||
| Q3 24 | $141.5M | — | ||
| Q2 24 | $143.3M | — | ||
| Q1 24 | $143.2M | — |
股东权益LPRORGNX
| Q4 25 | $75.0M | $102.7M | ||
| Q3 25 | $72.8M | $161.5M | ||
| Q2 25 | $78.9M | $213.7M | ||
| Q1 25 | $79.8M | $274.2M | ||
| Q4 24 | $78.1M | $259.7M | ||
| Q3 24 | $220.5M | $301.4M | ||
| Q2 24 | $216.8M | $348.3M | ||
| Q1 24 | $211.5M | $390.7M |
总资产LPRORGNX
| Q4 25 | $236.7M | $453.0M | ||
| Q3 25 | $287.7M | $525.2M | ||
| Q2 25 | $296.7M | $581.0M | ||
| Q1 25 | $304.2M | $490.9M | ||
| Q4 24 | $296.4M | $466.0M | ||
| Q3 24 | $395.7M | $519.1M | ||
| Q2 24 | $382.8M | $569.4M | ||
| Q1 24 | $380.6M | $629.2M |
负债/权益比LPRORGNX
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 1.73× | — | ||
| Q4 24 | 1.79× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-3.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | -16.8% | -174.0% |
| 资本支出强度资本支出/营收 | 0.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LPRORGNX
| Q4 25 | $-3.2M | $-52.3M | ||
| Q3 25 | $-5.7M | $-56.0M | ||
| Q2 25 | $848.0K | $-49.3M | ||
| Q1 25 | $-3.8M | $33.6M | ||
| Q4 24 | $17.6M | $-31.6M | ||
| Q3 24 | $11.4M | $-40.5M | ||
| Q2 24 | $-1.4M | $-45.5M | ||
| Q1 24 | $11.0M | $-55.5M |
自由现金流LPRORGNX
| Q4 25 | $-3.3M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $837.0K | $-49.7M | ||
| Q1 25 | $-3.9M | $32.6M | ||
| Q4 24 | $17.4M | $-32.7M | ||
| Q3 24 | $11.3M | $-40.9M | ||
| Q2 24 | $-1.5M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率LPRORGNX
| Q4 25 | -16.8% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | 3.3% | -232.8% | ||
| Q1 25 | -15.9% | 36.6% | ||
| Q4 24 | -30.6% | -154.2% | ||
| Q3 24 | 48.0% | -168.9% | ||
| Q2 24 | -5.5% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度LPRORGNX
| Q4 25 | 0.3% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | -0.3% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率LPRORGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | -6.22× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | -0.48× | — | ||
| Q1 24 | 2.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LPRO
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
